

ASX Announcement



Orthocell Appoints Exclusive Remplir™ Distributor for US\$84 million Thai Nerve Repair Market

- **MediTime appointed as exclusive in-country distributor of Remplir™ in Thailand**, providing Orthocell with an established commercial pathway into the US\$84 million¹ Thai nerve repair market.
- **MediTime is a specialist orthopaedics and sports medicine distributor backed by** the broader regional infrastructure and commercial expertise of **Device Technologies Group**, Orthocell's existing distribution partner across Australia, New Zealand and Singapore, extending the Company's successful regional partnership.
- **MediTime's established clinical education platform**, key opinion leader (KOL) relationships, hospital access and national logistics network position Orthocell to drive surgeon engagement and accelerate adoption of Remplir throughout Thailand.
- **The appointment builds on regulatory approval from the Thailand FDA** to commercialise Remplir in Thailand and further strengthens Orthocell's expanding Asian distribution network, with product sales underway in Australia, Singapore and Hong Kong.
- **Orthocell continues to execute its distributor-led commercial strategy** across key non-U.S. markets, while focusing internal resources on the Company-led U.S. market, where recent approvals have expanded access to approximately 336 hospitals, including 221 U.S. military medical centres.
- **The Company remains well funded**, with over A\$48 million in cash as at 31 March 2026 and no debt, supporting continued commercial expansion.

Perth, Australia; 03 July 2026: Regenerative medicine company Orthocell Limited (ASX: OCC, "Orthocell" or the "Company") is pleased to announce the appointment of MediTime as its exclusive in-country distributor for its nerve repair product Remplir in Thailand.

The appointment follows Orthocell receiving regulatory approval from the Thai Food and Drug Administration in CY25 to commence sales of Remplir into the Thai market, which is estimated to be worth approximately US\$84 million.

As a sophisticated healthcare market with a well-developed hospital system and strong medical tourism sector, Thailand represents a strategically important component of Orthocell's Asian commercialisation strategy.

MediTime is a specialist orthopaedics and sports medicine distributor with established coverage across leading hospitals, medical schools and regional centres in Thailand. They have built a strong commercial

¹ Nerve repair market sizes estimated using reference papers from both US and OUS databases and studies.

position in upper extremity orthopaedic surgery, providing direct access to Orthocell's core customer base of orthopaedic and plastic surgeons.

MediTime's model is underpinned by surgeon education and strong relationships with key opinion leaders, supporting both near-term adoption and long-term market development.

The appointment extends Orthocell's successful relationship with Device Technologies Group, which supports Remplir distribution in Australia, New Zealand and Singapore.

Orthocell Managing Director Paul Anderson said: "The appointment of MediTime as our exclusive distributor in Thailand is an important step in executing our Asian commercialisation strategy for Remplir. Thailand represents a high-quality healthcare market with strong underlying demand for advanced nerve repair solutions.

MediTime's established clinical relationships, education-driven model and national distribution capability make them an ideal partner to support the successful introduction of Remplir.

Importantly, this appointment further strengthens our successful relationship with Device Technologies Group as we continue to build out our distribution network across Asia."

Orthocell will continue to execute its distributor-led commercial strategy across key non-U.S. markets, with limited incremental internal resources to support the commercialisation process in those markets. Internal resources will continue to focus on the Company-led U.S. market, where recent approvals have expanded access to a growing network of ~336 hospitals, including 221 U.S. military medical centres.

Release authorised by:
Paul Anderson
Orthocell Ltd CEO and MD

For more information, please contact:

General enquiries

Paul Anderson
Orthocell Limited
CEO and MD
P: +61 8 9360 2888
E: paul.anderson@orthocell.com

Media enquiries

Haley Chartres
H^CK Director
P: +61 423 139 163
E: haley@hck.digital

Investor enquiries

Shaun Duffy
VECTOR Advisors
P: +61 404 094 384
E: sduffy@vectoradvisors.au

About Orthocell Limited

ACN 118 897 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed a network of specialist US distributors and recorded initial sales. The Company's flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand, Canada and Hong Kong. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @OrthocellLtd and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.